Functional screening for anti-CMV biologics identifies a broadly neutralizing epitope of an essential envelope protein

Nature Communications

Volumn 7, Issue , 2016, Pages

  Gardner, Thomas J ^a   Stein, Kathryn R ^a   Duty, J Andrew ^a   Schwarz, Toni M ^a   Noriega, Vanessa M ^a   Kraus, Thomas ^a   Moran, Thomas M ^a   Tortorella, Domenico ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN; GLYCOPROTEIN H; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; GLYCOPROTEIN H, CYTOMEGALOVIRUS; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ANTIBODY; ANTIGEN; BIOASSAY; CELLS AND CELL COMPONENTS; NEUTRALIZATION; PROTEIN; ROBOTICS; VACCINE; VIRUS;

ALPHA HELIX; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SCREENING; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG IDENTIFICATION; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNIZATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN TARGETING; ROBOTICS; VIRUS ENTRY; VIRUS NEUTRALIZATION; ANIMAL; CELL LINE; CHEMISTRY; CYTOMEGALOVIRUS; IMMUNOLOGY; PATHOGENICITY;

HERPESVIRIDAE; HUMAN HERPESVIRUS 5;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; MICE; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; VIRUS INTERNALIZATION;

EID: 85005993363     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13627     Document Type: Article

References (70)

1. Reinke, P., Prosch, S., Kern, F., Volk, H. D. Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl. Infect. Dis. 1, 157-164 (1999).
2. Khan, N. The immunological burden of human cytomegalovirus infection. Arch. Immunol. Ther. Exp. (Warsz) 55, 299-308 (2007).
3. Damato, E. G., Winnen, C. W. Cytomegalovirus infection: perinatal implications. J. Obstet. Gynecol. Neonatal Nurs. 31, 86-92 (2002).
4. Connolly, S. A., Jackson, J. O., Jardetzky, T. S., Longnecker, R. Fusing structure and function: a structural view of the herpesvirus entry machinery. Nat. Rev. Microbiol. 9, 369-381 (2011).
5. Burke, H. G., Heldwein, E. E. Crystal structure of the human cytomegalovirus glycoprotein B. PLoS Pathog. 11, e1005227 (2015).
6. Spindler, N. et al. Structural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibody. PLoS Pathog. 10, e1004377 (2014).
7. Vanarsdall, A. L., Ryckman, B. J., Chase, M. C., Johnson, D. C. Human cytomegalovirus glycoproteins gB and gH/gL mediate epithelial cell-cell fusion when expressed either in cis or in trans. J. Virol. 82, 11837-11850 (2008).
8. Compton, T., Nepomuceno, R. R., Nowlin, D. M. Human cytomegalovirus penetrates host cells by pH-independent fusion at the cell surface. Virology 191, 387-395 (1992).
9. Ryckman, B. J., Jarvis, M. A., Drummond, D. D., Nelson, J. A., Johnson, D. C. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J. Virol. 80, 710-722 (2006).
10. Wille, P. T., Knoche, A. J., Nelson, J. A., Jarvis, M. A., Johnson, D. C. A human cytomegalovirus gO-null mutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells. J. Virol. 84, 2585-2596 (2010).
11. Jiang, X. J. et al. UL74 of human cytomegalovirus contributes to virus release by promoting secondary envelopment of virions. J. Virol. 82, 2802-2812 (2008).
12. Zhou, M., Lanchy, J. M., Ryckman, B. J. Human Cytomegalovirus gH/gL/gO promotes the fusion step of entry into all cell types, whereas gH/gL/UL128-131 broadens virus tropism through a distinct mechanism. J. Virol. 89, 8999-9009 (2015).
13. Wang, D., Shenk, T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl Acad. Sci. USA 102, 18153-18158 (2005).
14. Hahn, G. et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol. 78, 10023-10033 (2004).
15. Gerna, G. et al. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8\+ T cells. J. Gen. Virol. 86, 275-284 (2005).
16. Chou, S., Marousek, G., Li, S., Weinberg, A. Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. J. Clin. Virol. 43, 107-109 (2008).
17. Reed, E. C., Bowden, R. A., Dandliker, P. S., Lilleby, K. E., Meyers, J. D. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann. Intern. Med. 109, 783-788 (1988).
18. Snydman, D. R. et al. A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial. Transplant. Proc. 20, 24-30 (1988).
19. Snydman, D. R. et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N. Engl. J. Med. 317, 1049-1054 (1987).
20. Japanese Congenital Cytomegalovirus Infection Immunoglobulin Fetal Therapy Study Group. A trial of immunoglobulin fetal therapy for symptomatic congenital cytomegalovirus infection. J. Reprod. Immunol. 95, 73-79 (2012).
21. Visentin, S. et al. Early primary cytomegalovirus infection in pregnancy: maternal hyperimmunoglobulin therapy improves outcomes among infants at 1 year of age. Clin. Infect. Dis. 55, 497-503 (2012).
22. Nigro, G. et al. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy-a case-control study of the outcome in children. J. Infect. Dis. 205, 215-227 (2012).
23. Buxmann, H. et al. Use of cytomegalovirus hyperimmunoglobulin for prevention of congenital cytomegalovirus disease: a retrospective analysis. J. Perinat. Med. 40, 439-446 (2012).
24. Revello, M. G. et al. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N. Engl. J. Med. 370, 1316-1326 (2014).
25. Ohlin, M., Soderberg-Naucler, C. Human antibody technology and the development of antibodies against cytomegalovirus. Mol. Immunol. 67, 153-170 (2015).
26. Potzsch, S. et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog. 7, e1002172 (2011).
27. Ohlin, M., Sundqvist, V. A., Mach, M., Wahren, B., Borrebaeck, C. A. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J. Virol. 67, 703-710 (1993).
28. Britt, W. J., Vugler, L., Butfiloski, E. J., Stephens, E. B. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J. Virol. 64, 1079-1085 (1990).
29. Cui, X., Meza, B. P., Adler, S. P., McVoy, M. A. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26, 5760-5766 (2008).
30. Kabanova, A. et al. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc. Natl Acad. Sci. USA 111, 17965-17970 (2014).
31. Macagno, A. et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J. Virol. 84, 1005-1013 (2010).
32. Freed, D. C. et al. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc. Natl Acad. Sci. USA 110, E4997-E5005 (2013).
33. Genini, E. et al. Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J. Clin. Virol. 52, 113-118 (2011).
34. Fouts, A. E., Chan, P., Stephan, J. P., Vandlen, R., Feierbach, B. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J. Virol. 86, 7444-7447 (2012).
35. Gardner, T. J. et al. Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies. Clin. Vaccine Immunol. 20, 540-550 (2013).
36. Gardner, T. J. et al. Development of a high-content screen for the identification of inhibitors directed against the early steps of the cytomegalovirus infectious cycle. Antiviral Res. 113, 49-61 (2015).
37. Britt, W. J., Auger, D. Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus. J. Virol. 58, 185-191 (1986).
38. Akter, P. et al. Two novel spliced genes in human cytomegalovirus. J. Gen. Virol. 84, 1117-1122 (2003).
39. Wang, D., Shenk, T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J. Virol. 79, 10330-10338 (2005).
40. Murphy, E. et al. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc. Natl Acad. Sci. USA 100, 14976-14981 (2003).
41. Noriega, V. M. et al. Human cytomegalovirus US28 facilitates cell-to-cell viral dissemination. Viruses 6, 1202-1218 (2014).
42. Krampe, K., Briem-Richter, A., Fischer, L., Nashan, B., Ganschow, R. The value of immunoprophylaxis for cytomegalovirus infection with intravenous immunoglobulin in pediatric liver transplant recipients receiving a low-dose immunosupressive regimen. Pediatr. Transplant. 14, 67-71 (2010).
43. Huber, M. T., Compton, T. The human cytomegalovirus UL74 gene encodes the third component of the glycoprotein H-glycoprotein L-containing envelope complex. J. Virol. 72, 8191-8197 (1998).
44. Chowdary, T. K. et al. Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. Nat. Struct. Mol. Biol. 17, 882-888 (2010).
45. Ciferri, C. et al. Structural and biochemical studies of HCMV gH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes. Proc. Natl Acad. Sci. USA 112, 1767-1772 (2015).
46. Fouts, A. E. et al. Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109. Proc. Natl Acad. Sci. USA 111, 8209-8214 (2014).
47. Schultz, E. P., Lanchy, J. M., Ellerbeck, E. E., Ryckman, B. J. Scanning mutagenesis of human cytomegalovirus glycoprotein gH/gL. J. Virol. 90, 2294-2305 (2016).
48. Zhou, M., Yu, Q., Wechsler, A., Ryckman, B. J. Comparative analysis of gO isoforms reveals that strains of human cytomegalovirus differ in the ratio of gH/gL/gO and gH/gL/UL128-131 in the virion envelope. J. Virol. 87, 9680-9690 (2013).
49. Noriega, V., Redmann, V., Gardner, T., Tortorella, D. Diverse immune evasion strategies by human cytomegalovirus. Immunol. Res. 54, 140-151 (2012).
50. Gardner, T. J., Tortorella, D. Virion glycoprotein-mediated immune evasion by human cytomegalovirus: a sticky virus makes a slick getaway. Microbiol. Mol. Biol. Rev. 80, 663-677 (2016).
51. Renzette, N., Bhattacharjee, B., Jensen, J. D., Gibson, L., Kowalik, T. F. Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog. 7, e1001344 (2011).
52. Gorzer, I., Guelly, C., Trajanoski, S., Puchhammer-Stockl, E. Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time. J. Virol. 84, 7195-7203 (2010).
53. Ciferri, C. et al. Antigenic characterization of the HCMV gH/gL/gO and pentamer cell entry complexes reveals binding sites for potently neutralizing human antibodies. PLoS Pathog. 11, e1005230 (2015).
54. Presta, L. G. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 20, 460-470 (2008).
55. Borucki, M. J. et al. A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res. 64, 103-111 (2004).
56. MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Monoclonal Antibody Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group. AIDS Clinical Trials Group. Arch Ophthalmol 115, 1528-1536 (1997).
57. Gilpin, A. M., Holbrook, J. T., Jabs, D. A., Meinert, C. L. (Studies of Ocular Complications of AIDS Research Group). Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial. Control Clin. Trials 24, 92-98 (2003).
58. Boeckh, M. et al. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 7, 343-351 (2001).
59. Manley, K. et al. Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe. 10, 197-209 (2011).
60. Lantto, J. et al. Capturing the natural diversity of the human antibody response against vaccinia virus. J. Virol. 85, 1820-1833 (2011).
61. Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47-53 (2014).
62. Bregenholt, S., Jensen, A., Lantto, J., Hyldig, S., Haurum, J. S. Recombinant human polyclonal antibodies: a new class of therapeutic antibodies against viral infections. Curr. Pharm. Des. 12, 2007-2015 (2006).
63. Bregenholt, S., Haurum, J. Pathogen-specific recombinant human polyclonal antibodies: biodefence applications. Expert Opin. Biol. Ther. 4, 387-396 (2004).
64. Simpson, J. A. et al. Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J. Virol. 67, 489-496 (1993).
65. Urban, M., Britt, W., Mach, M. The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J. Virol. 66, 1303-1311 (1992).
66. Noriega, V. M. et al. Human cytomegalovirus US3 modulates destruction of MHC class I molecules. Mol. Immunol. 51, 245-253 (2012).
67. Tiller, T., Busse, C. E., Wardemann, H. Cloning and expression of murine Ig genes from single B cells. J. Immunol. Methods 350, 183-193 (2009).
68. Kuramochi, T., Igawa, T., Tsunoda, H., Hattori, K. Humanization and simultaneous optimization of monoclonal antibody. Methods Mol. Biol. 1060, 123-137 (2014).
69. Lyskov, S. et al. Serverification of molecular modeling applications: the Rosetta Online Server that Includes Everyone (ROSIE). PLoS ONE 8, e63906 (2013).
70. Sivasubramanian, A., Sircar, A., Chaudhury, S., Gray, J. J. Toward high-resolution homology modeling of antibody Fv regions and application to antibody-antigen docking. Proteins 74, 497-514 (2009).